ArticleChest2025
Proteomic Analysis of Nasopharyngeal Aspirate Biomarkers for Prematurity-Related Bronchopulmonary Dysplasia.
Article in Chest, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04785859 (Multiparametric Prediction of the Risk of Moderate-severe Bronchopulmonary Dysplasia in Neonates Born Before 30 Weeks of Gestation), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multiparametric Prediction of the Risk of Moderate-severe Bronchopulmonary Dysplasia in Neonates Born Before 30 Weeks of Gestation
Who cites it
2 citing papers in PubMed.
- Qualitative assessment of nasopharyngeal aspirates as an alternative to tracheal aspirates in extremely preterm infants.Frontiers in pediatrics · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe high incidence of bronchopulmonary dysplasia (BPD) continues to be a problem among extremely low-gestational-age neonates (ELGANs). Recent improvements in next-generation proteomics have provided opportunities to obtain new perspectives on the early detection of BPD. In this study, our main objectives were to study the proteomes of patients by collecting nasopharyngeal aspirate (NPA) samples and evaluate the differences between ELGANs with and without BPD at 1 week of life. RESEARCH QUESTION: Is it possible to identify differential NPA biomarkers for the early detection of BPD at 1 week of life? STUDY DESIGN AND
methodsA cohort of infants without and with BPD born before 30 gestational weeks was selected. NPA samples were collected 1 week after birth by trained nurses and processed for next-generation proteomics using relevant protocols. The resulting protein matrix was used for exploratory, differential expression, and functional enrichment analyses; modeling; and variable reduction.
resultsThe data from 131 ELGANs (74 without BPD, 43 with BPD, and 14 deceased) were included. The optimal area under the curve (AUC) values were reached via sparse partial least discrimination analysis (2 components: AUC, 0.95; 95% CI, 0.91-0.99; P < .001). Seventy-three differentially expressed proteins were identified (|log
interpretationThe results of this study indicate that studying the proteomes of NPA samples can aid in early BPD diagnosis at 1 week of age in infants born before 30 weeks of gestation. This approach may be useful for increasing the understanding of BPD pathophysiology in ELGANs. CLINICAL
trial registrationClinicalTrials.gov; No.: NCT04785859; URL: www. CLINICALTRIALS: gov.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.